Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers

Abstract Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC), contributing to tumour progression, metastatic dissemination and immune evasion. Hypoxia‐induced angiogenic signalling sustai...

Description complète

Détails bibliographiques

Auteurs principaux:	Maria Rosaria Lamia, Erica Perri, Gustavo Baldassarre, Sandro Pignata, Chiara D'Alessio, Davide Limongello, Francesca Basso‐Valentina
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2026-01-01
Collection:	Clinical and Translational Medicine
Sujets:	angiogenesis bevacizumab homologous recombination deficiency (HRD) ovarian cancer PARP inhibitors predictive biomarkers
Accès en ligne:	https://doi.org/10.1002/ctm2.70591
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!